<code id='4447A5BB51'></code><style id='4447A5BB51'></style>
    • <acronym id='4447A5BB51'></acronym>
      <center id='4447A5BB51'><center id='4447A5BB51'><tfoot id='4447A5BB51'></tfoot></center><abbr id='4447A5BB51'><dir id='4447A5BB51'><tfoot id='4447A5BB51'></tfoot><noframes id='4447A5BB51'>

    • <optgroup id='4447A5BB51'><strike id='4447A5BB51'><sup id='4447A5BB51'></sup></strike><code id='4447A5BB51'></code></optgroup>
        1. <b id='4447A5BB51'><label id='4447A5BB51'><select id='4447A5BB51'><dt id='4447A5BB51'><span id='4447A5BB51'></span></dt></select></label></b><u id='4447A5BB51'></u>
          <i id='4447A5BB51'><strike id='4447A5BB51'><tt id='4447A5BB51'><pre id='4447A5BB51'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:35323
          Cambridge: Biogen
          Ruby Wallau for STAT

          Biogen, the iconic but embattled biotech firm, is shuttering Biogen Digital Health, its roughly 150-person group focused on using new types of data like those from mobile phones and smart watches, and ending a clinical trial being conducted with Apple early, STAT has learned.

          Biogen confirmed the organizational change, but said it might lean even more on digital tech startups in the future.

          advertisement

          “It’s certainly not an abandonment of digital, it’s more of a realignment of resources and priorities,” said Adam Keeney, Biogen’s executive vice president and head of corporate development. However, he later acknowledged, Biogen Digital Health, a separate entity, “would no longer continue in its current form.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          Deposition: Sackler embraced plan to conceal OxyContin’s strength
          Deposition: Sackler embraced plan to conceal OxyContin’s strength

          RichardSacklerMollyFergusonforSTATThisstoryisacollaborationbetweenSTATandProPublica.InMay1997,theyea

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Cigna wins case to block Amy Bricker's move to CVS

          AdobeCVSHealthviewedAmyBrickerasapotentialCEO.Butshewon’tbegoingtothehealthcareconglomerateanytimeso